Multiple Myeloma Research Foundation: Powerful thinking advances the cure  
    Add page Bookmark this page Add page Print this page
DONATE NOW   LOGIN|JOIN MMRF TODAY!
 
SEARCH
 
  • About The MMRF
    • Powerful Mission
    • Leadership
    • Powerful Model
    • Results
    • Powerful News
    • Financial Reports
    • Employment Opportunities
  • living with multiple myeloma
    • Newly Diagnosed Patients
    • Patients Starting Treatment
    • Relapsed/Refractory Patients
    • Clinical Trials
    • Educational Programs
    • Additional Resources
  • Research Programs
    • CoMMpass℠ Study
    • Genomics Initiative
    • Results
    • Scientific Agenda
    • For Academic Researchers
    • For Industry
  • Donate Now/Take Action
    • Ways to Donate
    • Join an Event
    • Shop MMRF
Newly Diagnosed Patients
Patients Starting Treatment
Relapsed/Refractory Patients
Your Top Questions Answered
Treatment Options
Clinical Trials
Educational Programs
Treatment Options
Additional Resources

REGISTER TODAY!

Register your email address with us so we can be in touch with the information you need - when you need it most.



C-MAP LAUNCHED

MMRF & Onyx launch Carfilzomib Myeloma Access Program (C-MAP) for patients with multiple myeloma. Click here to learn more.

The MMRF > Living with Multiple Myeloma > Relapsed/Refractory Patients

Relapsed/Refractory Patients



Dealing with relapsed/refractory disease has its own unique challenges. Here you will learn about the latest treatment options and find the help you need to navigate through this next phase in your multiple myeloma disease.


Learn More about the MMRF accreditaions
go Learn more about the MMRF Accreditations
facebook  Become a fan on Facebook
YouTube  See our videos on YouTube
Twitter  Follow us on Twitter
Contact us Corporate Supporters | Terms of Use | Privacy Policy 

Copyright © 2012 Multiple Myeloma Research Foundation 
 

Powered by Convio
nonprofit software